BRCA1 and neoplasm: The literature indicates that olaparib can be cautiously preferred over capecitabine as adjuvant therapy in BRCA1/2 germline pathogenic variant TNBC cases as the PARPi directly targets the deoxyribonucleic acid (DNA) damage repair pathway implicated in this tumour subset.